Arboris at the “Innovating Health: Israel–China Collaboration in Medical Technologies” Forum in Shanghai
Main event visual at the “Innovating Health: Israel–China Collaboration in Medical Technologies” forum. The event was held in Shanghai on 26 November 2025, organised by Sino-Israeli Innovation (Taixing) Technology Development Co., Ltd. with support from the Consulate General of Israel in Shanghai.
Arboris Global Partners was present at the “Innovating Health: Israel–China Collaboration in Medical Technologies” forum held in Shanghai on 26 November 2025. The event was organised by Sino-Israeli Innovation (Taixing) Technology Development Co., Ltd. with support from the Consulate General of Israel in Shanghai, and took place at the Jade Room of Grand Hotel Shanghai. The forum focused on opportunities for collaboration between Israel and China in medical technology, with particular attention to AI-enabled healthcare, precision oncology, telehealth, and translational pathways in medical innovation. More than one hundred healthcare professionals, investors, and researchers were present for discussion.
The forum opened with a keynote by Jie Yucheng on the status and outlook of Israel–China cooperation. Ravit Baer, Consul General of Israel in Shanghai, also delivered remarks noting the strength of bilateral cooperation in science and innovation and identifying medical technology as a significant area of future collaboration. The event brought together participants from healthcare, investment, and research communities to discuss the application of medical innovation in the China market.
Forum Q&A session. Specialists from Hadassah Medical Center exchanged views with participants on AI-enabled healthcare, precision oncology, telehealth, and innovation-commercialisation models.
The core programme featured specialist presentations from Hadassah Medical Center. Professor Yaron Ilan, Deputy Director General of Hadassah, introduced the centre’s innovation culture and history and discussed an AI system based on biological variability analysis for disease-risk prediction and treatment optimisation. Professor Shai Rosenberg, Head of Computational Medicine, addressed AI-driven precision oncology and demonstrated how genomic and other multi-source data may be integrated to support personalised cancer treatment. Dr Ravit Barkama, Director of the virtual hospital, discussed the role of telehealth in improving accessibility and quality of care, and explained how Hadassah’s virtual-hospital model extends specialist services beyond conventional clinical settings into communities and homes. Mr Amir Dagan, Chief Executive Officer of Hadassah’s innovation and entrepreneurship company, outlined the institution’s model for innovation translation through incubation, investment, and IP-led commercialisation.
Arboris representatives in discussion with participants during the forum.
The forum was not limited to technical presentation alone. Participants discussed technology deployment, investment cooperation, and joint R&D, giving the event both a professional-exchange function and a practical role as a platform for industrial coordination and resource linkage. During its time in Shanghai, the Hadassah delegation also visited the Shanghai Municipal Health Commission, Shanghai Jiao Tong University School of Medicine, and Longhua Hospital, holding discussions on staff training, joint project development, commercialisation of clinical outcomes, AI innovation, and ageing-related healthcare issues.
In Arboris’s view, the significance of this type of exchange lies not only in presenting individual technological advances, but in understanding how cross-border healthcare collaboration can be translated into workable pathways across institutional, capital, and industry frameworks. For professional and institutional participants, durable value depends not only on technical novelty, but also on the cooperation mechanisms, governance arrangements, knowledge-transfer pathways, and execution conditions that support commercial adoption.
From that perspective, the themes addressed at the forum—including AI in healthcare, precision medicine, telehealth, and innovation-commercialisation models—are directly relevant to Arboris’s broader focus on cross-border collaboration, structured execution, and long-horizon value formation. Whether in the context of institutional capital, industrial partnerships, or cross-border project development, clear cooperation frameworks, disciplined execution, and stable institutional environments remain central to translating opportunity into durable outcomes.
On-site exchange during the forum.
Arboris will continue to follow developments in medical technology, cross-border collaboration, and related innovation ecosystems, and to support professional and institutional clients through governance-led execution, cross-border structuring, and long-term capital coordination.
About Arboris Global Partners
Arboris Global Partners is a Singapore-headquartered capital strategy and advisory platform serving professional and institutional clients across wealth management, asset strategies, fund platforms, family-office governance, and capital structure and planning. The firm draws on experience in Australian real-estate credit and Asian secondary private markets, with an approach grounded in prudence, discipline, and trust.